This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Riess, G
Right arrow Articles by Wise, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Riess, G
Right arrow Articles by Wise, R

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1992 November; 36(11): 2360-2364

In vitro activity of RU 29246, the active compound of the cephalosporin prodrug ester HR 916.

G Riess, J Andrews, D Thornber and R Wise

Department of Microbiology, Dudley Road Hospital, Birmingham, United Kingdom.

ABSTRACT

The in vitro activity of RU 29246 was compared with those of other agents against 536 recent clinical isolates. The MICs of RU 29246 for 90% of members of the family Enterobacteriaceae tested (MIC90s) were less than 2 micrograms/ml except those for Morganella spp. (16 micrograms/ml) and Proteus spp. (8 micrograms/ml). RU 29246 was active against Staphylococcus aureus (MIC90, < or = 8 micrograms/ml) and against Staphylococcus saprophyticus and coagulase-negative staphylococci (MIC90s, < or = 2 micrograms/ml). Streptococci and Neisseria gonorrhoeae were highly susceptible to RU 29246, and the activity of the agent against isolates of Streptococcus pneumoniae (MIC90, < or = 0.5 micrograms/ml), Haemophilus influenzae (MIC90, < or = 2 micrograms/ml), and Moraxella catarrhalis (MIC90, < or = 2 micrograms/ml) was comparable to those of the other cephalosporins tested. RU 29246 was insusceptible to hydrolysis by the common plasmid-mediated beta-lactamases (TEM-1 and SHV-1). However, hydrolysis by the new extended-spectrum beta-lactamases (TEM-3, TEM-5, and TEM-9) was detected. Results of the study suggested that RU 29246 should be investigated clinically for use in the treatment of a wide range of infections.

Antimicrob Agents Chemother. 1992 November; 36(11): 2360-2364




This article has been cited by other articles:

  • Paker, G. E., Graham, J. A., Rauch, A. M., Collins, J. J. (1994). Cefuroxime Axetil in the Treatment of Sinusitis: A Review. Arch Fam Med 3: 165-175 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»